Altered expression and splicing of ESRP1 in malignant melanoma correlates with epithelial- mesenchymal status and Tumor-Associated immune cytolytic activity

Cancer Immunology Research

Volumn 4, Issue 6, 2016, Pages 552-561

  Yao, Jun ^a   Caballero, Otavia L ^b,c   Huang, Ying ^d   Lin, Calvin ^d   Rimoldi, Donata ^e   Behren, Andreas ^f   Cebon, Jonathan S ^f   Hung, Mien Chie ^a   Weinstein, John N ^a   Strausberg, Robert L ^g   Zhao, Qi ^b,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Orygen Biotecnologia   (Brazil)

^d REGENERON PHARMACEUTICALS INC   (United States)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

^f OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^g LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 LIGAND 2; PROTEIN ESRP1; REGULATOR PROTEIN; UNCLASSIFIED DRUG; ESRP1 PROTEIN, HUMAN; RNA BINDING PROTEIN; TRANSCRIPTOME; TUMOR MARKER; TUMOR PROTEIN;

ANIMAL CELL; ARTICLE; CANCER SURVIVAL; CELL PLASTICITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; EPITHELIAL MESENCHYMAL TRANSITION; EXON; GENE EXPRESSION; GENE MUTATION; MELANOCYTE; MELANOMA; MELANOMA CELL LINE; MOUSE; NONHUMAN; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; RNA SPLICING; ALTERNATIVE RNA SPLICING; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PROGNOSIS; SECONDARY;

ALTERNATIVE SPLICING; BIOMARKERS, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DATABASES, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOCYTES; MELANOMA; NEOPLASM PROTEINS; PROGNOSIS; RNA-BINDING PROTEINS; TRANSCRIPTOME;

EID: 84976592674     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0255     Document Type: Article

References (34)

1. Hoek KS, Goding CR. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res 2010;23:746-59.
2. Ghislin S, Deshayes F, Middendorp S, Boggetto N, Alcaide-Loridan C. PHF19 and Akt control the switch between proliferative and invasive states in melanoma. Cell Cycle 2012;11:1634-45.
3. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 2006;19: 290-302.
4. Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 2006;12: 406-14.
5. Strub T, Giuliano S, Ye T, Bonet C, Keime C, Kobi D, et al. Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. Oncogene 2011;30:2319-32.
6. Carreira S, Goodall J, Denat L, Rodriguez M, Nuciforo P, Hoek KS, et al. Mitf regulation ofDia 1 controls melanoma proliferation and invasiveness. Gen Dev 2006;20:3426-39.
7. Koludrovic D, Davidson I. MITF, the janus transcription factor of melanoma. Fut Oncol 2013;9:235-44.
8. Grossmann AH, Yoo JH, Clancy J, Sorensen LK, Sedgwick A, Tong Z, et al. The small GTPase ARF6 stimulates beta-catenin transcriptional activity during WNT5A-mediated melanoma invasion and metastasis. Sci Sig 2013;6:ra14.
9. Bachmann IM, Straume O, Puntervoll HE, Kalvenes MB, Akslen LA. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 2005;11:8606-14.
10. Chien AJ, Conrad WH, Moon RT. A Wnt survival guide: from flies to human disease. J Invest Dermatol 2009;129:1614-27.
11. Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, Berger AJ, et al. Activated Wnt/beta-catenin signaling inmelanoma is associated with decreased proliferation in patient tumors and a murinemelanoma model. Proc Natl Acad Sci U S A 2009;106:1193-8.
12. O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov 2013;3:1378-93.
13. Warzecha CC, Shen S, Xing Y, Carstens RP. The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events. RNA Biol 2009;6:546-62.
14. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell 2009;33:591-601.
15. Zhao Q, Caballero OL, Davis ID, Jonasch E, Tamboli P, Yung WK, et al. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clin Cancer Res 2013;19:2460-72.
16. Theveneau E, Mayor R. Neural crest delamination and migration: from epithelium-to-mesenchyme transition to collective cell migration. Dev Biol 2012;366:34-54.
17. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelialmesenchymal transitions: The importance of changing cell state in development and disease. J Clin Invest 2009;119:1438-49.
18. Shakhova O.Neural crest stem cells in melanoma development. Curr Opin Oncol 2014;26:215-21.
19. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 2015;161:1681-96.
20. Pico de Coana Y, Choudhury A, Kiessling R. Checkpoint blockade for cancer therapy: Revitalizing a suppressed immune system. Trends Mol Med 2015;21:482-91.
21. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
22. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
23. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 2014;5:5241.
24. Warzecha CC, Jiang P, Amirikian K, Dittmar KA, Lu H, Shen S, et al. An ESRP-regulated splicing programme is abrogated during the epithelialmesenchymal transition. Embo J 2010;29:3286-300.
25. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015;160:48-61.
26. Sommer L.Generation ofmelanocytes from neural crest cells. Pigment Cell Melanoma Res 2011;24:411-21.
27. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406:536-40.
28. John T, Black MA, Toro TT, Leader D, Gedye CA, Davis ID, et al. Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res 2008;14:5173-80.
29. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 2006;98:472-82.
30. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015;348:62-8.
31. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56-61.
32. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30:825-30.
33. Flockhart RJ, Webster DE, Qu K, Mascarenhas N, Kovalski J, Kretz M, et al. BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration. Genome Res 2012;22:1006-14.
34. Pawlikowski JS, McBryan T, van Tuyn J, Drotar ME, Hewitt RN, Maier AB, et al. Wnt signaling potentiates nevogenesis. Proc Natl Acad Sci U S A 2013;110:16009-14.